Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control

Hiren Divecha1, Naveed Sattar, Ann Rumley

  • 1Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Scotland, UK.

Insights

Men with ankylosing spondylitis (AS) have increased coronary heart disease (CHD) risk factors, primarily driven by systemic inflammation. Controlling for inflammation significantly reduced observed risk factor differences in AS patients.

Area of Science:

  • Rheumatology and Cardiology
  • Inflammation and Cardiovascular Disease Research

Background:

  • Men with ankylosing spondylitis (AS) face a higher risk of coronary heart disease (CHD).
  • Information regarding specific risk factors and the influence of systemic inflammation in AS patients is limited.

Purpose of the Study:

  • To compare conventional and novel CHD risk factors in men with AS versus healthy controls.
  • To specifically investigate the impact of systemic inflammation on these risk factors in AS.

Main Methods:

  • Recruited 27 men with AS and 19 age-matched healthy controls, none on lipid-lowering therapy.
  • Measured plasma lipids, inflammatory markers (IL-6, CRP), hemostatic factors (vWF, fibrinogen), and anthropometrics (BMI, blood pressure).

Main Results:

  • AS patients showed higher rates of smoking, BMI, IL-6, CRP, fibrinogen, and vWF compared to controls.
  • After adjusting for BMI and smoking, elevated IL-6 and CRP were the primary drivers of other risk factor differences.
  • Inflammatory markers (IL-6) correlated with fibrinogen and inversely with total cholesterol.

Conclusions:

  • Men with AS exhibit multiple CHD risk factor disturbances.
  • Systemic inflammation, indicated by IL-6 and CRP, appears to be the principal driver of these risk factors.
  • Inflammation-driven atherogenesis likely contributes to the elevated CHD risk observed in AS.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...